Project R-15293

The pathological effect of a novel antibody, anti-UH-RA.329 antibody, predicting failure to respond to first-line therapy in RA patients, in a mouse model of arthritis. (Research)

Rheumatoid arthritis (RA), one of the most common autoimmune diseases, is characterized by inflammation of the synovium and is associated with autoantibodies that target self-antigens. About one-third of RA patients do not respond to current first-line therapy, leading to worsened outcomes. Our group recently identified three novel antibody biomarkers in RA patients who failed to respond to first-line treatment, including anti-UH- RA.329 antibody, which targets destructive synovial cells. This project aims to investigate the biological role of the anti-UH-RA.329 antibody in therapy response and RA disease progression using the collagen-induced arthritis (CIA) mouse model. This mouse model of arthritis will be used to elucidate the effects of this novel antibody on treatment response using clinical, histological, and functional assessments. Additionally, we will evaluate how this antibody influences RA disease progression in healthy and arthritic mice. Ultimately, this research will provide insight into the biological relevance of this novel antibody biomarker in the process of treatment response and disease progression, which can be used in the treatment and management of RA.

01 January 2025 - 31 December 2025